Free online tool helps prostate cancer patients save on out-of-pocket drug costs

A study shows that comparing Medicare Part D prescription plans can lead to significant savings in cost of cancer care

11:15 AM

Author | Nicole Fawcett

man at table writing down in living room
Getty Images

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a study finds.

For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly.

But by using an online Medicare plan finder tool, patients can compare pricing among all Part D drug plans offered in their area and select the most affordable plan.

Researchers from the University of Michigan Health Rogel Cancer Center found that the Medicare Part D Plan Finder, which is funded by the Centers for Medicare and Medicaid Services, can identify significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.

“Patients with Medicare Part D have dozens of different drug plans available to choose from, but most patients unfortunately are not aware of this. If they compare estimated costs, they could save thousands of dollars each year in drug costs. This could make a huge impact for patients with limited resources,” said lead study author Benjamin Pockros, M.D., M.B.A., a urology resident at Michigan Medicine.

The researchers looked at out-of-pocket costs for abiraterone and enzalutamide, using the Medicare Part D Plan Finder to compare within 12 different regions across the country that have prominent prostate cancer programs.

Out-of-pocket costs for abiraterone prescriptions ranged from $1,379 to $13,274 among all Part D plans.

The median potential cost savings among all 12 cities was $9,321. For enzalutamide, out-of-pocket cost ranged from $9,854 to $13,061.

The median potential cost savings among all 12 cities was $1,839. The study is published in Urology Practice.

“We know cancer can take a devastating physical, emotional and financial toll on patients. For those enrolled in Medicare Part D, this plan finder is free and easy to use, and hopefully one small step in improving cancer care in our country,” Pockros said.

The plan finder is available online at medicare.gov/plan-compare.

Patients enter their zip code and prescription drugs; the finder displays estimated annual out-of-pocket costs for local retail and mail order pharmacies.

Medicare offers an annual open enrollment period from Oct. 15-Dec. 7, during which people can switch plans.

More than 49 million Americans are enrolled in Medicare Part D, and some patients have up to 50 different plans to choose from. Despite significant cost differences, fewer than 30% of patients report comparing drug plan pricing.

The study authors urge providers to speak to patients about using the plan finder.

They are now leading a project funded by the Rogel Cancer Center and U-M Institute for Healthcare Policy and Innovation to help make cancer patients more aware of the Medicare Part D Plan Finder to help minimize out-of-pocket drug costs.

Additional authors: Christina Shabet; Kristian Stensland, M.D., M.P.H., M.S.; Lindsey Herrel, M.D., M.S.

Paper cited: “Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity,” Urology Practice. DOI: 10.1097/UPJ.0000000000000421


More Articles About: Cancer (Oncology) Prostate Cancer Prostate Conditions Cancer Treatment Hormonal Therapy for Cancer Health Care Delivery, Policy and Economics Hospitals & Centers Community Health
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories man dirt biking jumping hill in woods
Health Lab
Doctor helps one father’s race against lung cancer
Successful treatment of ALK-positive cancer is giving a patient hope for the future that includes trips around the motocross track and time with his wife and four kids.
outline drawing of pancreas on beige screen with green orange yellow and pink
Health Lab
Avoiding recovery delays with hospitalized pancreatitis
Acute pancreatitis is among the most common gastrointestinal conditions requiring inpatient hospital care in the United States. Balancing the signaling of the interleukin-22 protein and interleukin-22 binding protein is crucial to recovery from acute and chronic pancreatitis.
Cancer Aware
Focal therapy for prostate cancer
When treating for localized prostate cancer, surgery and radiation are usually what people hear about. However, there are other treatments that could be options under a heading of focal therapy. Dr. Andrew Wood, a urologic oncologist with U-M Health Rogel Cancer Center’s Weiser Center for Prostate Cancer talks about these options and which patients could benefit from them.
father and son standing together and book cover
Health Lab
One doctor’s American dream: to stop hate
Asian-American history is American history. William D. Chey shares his immigrant father’s legacy, his own experience and calls on youth to practice the values of diversity, equity and inclusion throughout their lives.
Kenneth Eisenberg and the late Frances Eisenberg
News Release
$40 million gift supports Michigan Medicine’s new specialty care facility in Troy and mental health research
A $40 million gift to Michigan Medicine from the Eisenberg Foundation will be honored with the naming of a center for specialty care that will be built in Troy, and will support depression prevention research.
Cancer Aware surrounded by a circle of multicolor ribbons
Cancer Aware
University of Michigan’s Impact on the Future of Cancer Care
Four University of Michigan faculty members have served as president of the American Society of Clinical Oncology, a rare distinction that only two other institutions can claim. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. In this episode, Nicole Fawcett, director of communications for the Rogel Cancer Center, sat down with four past ASCO Presidents and talked about the importance of the society, the impact it has had on cancer care and research as a whole and the impact here at U-M. Participants: Allen Lichter, MD, FASTRO Doug Blayney, MD Dan Hayes, MD Lori Pierce, MD